Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo  >  Chugai Pharmaceutical Co Ltd    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO LTD

(4519)
  Report  
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Chugai Pharmaceutical Co., Ltd. - Galderma Announces the Results of Phase 2b Study of Nemolizumab in Patients with Atopic Dermatitis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/01/2018 | 10:13am EDT

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today that Galderma, Nestle Skin Health's Medical Solutions Business issued a press release regarding the results of phase 2b study of nemolizumab (CIM331) created by Chugai in patients with moderate-to-severe atopic dermatitis to investigate the efficacy and safety of nemolizumab.

Please refer to the link below for details of the press release: Galderma Announces Positive Results from Phase 2b Study of Nemolizumab in Patients with Moderate-to-Severe Atopic Dermatitis

https://www.nestleskinhealth.com/news/galderma-announces-positive-results-phase-2b-study-nemolizumab-patients-moderate-severe-atopic

Contact:

Tomoko Shimizu

Tel: +81-3-3273-0881

Email: pr@chugai-pharm.co.jp

(C) 2018 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO LTD 0.44% 6880 End-of-day quote.11.33%
NESTLÉ 0.10% 97.26 Delayed Quote.21.75%
ROCHE HOLDING -0.83% 263.4 Delayed Quote.10.94%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CHUGAI PHARMACEUTICAL CO L
04/19CHUGAI PHARMACEUTICAL : Nemolizumab Shows Positive Results in Maruho's Phase 3 S..
AQ
04/17CHUGAI PHARMACEUTICAL CO LTD : quaterly earnings release
04/09Oncolys BioPharma Inc. - Conclusion of Exclusive Licensing and Capital Tie-up..
AQ
04/03CHUGAI PHARMACEUTICAL : GHIT selects joint research project on dengue by Chugai,..
AQ
04/02CHUGAI PHARMACEUTICAL : Business Transfer of ULCERLMIN for the Treatment of Gast..
AQ
04/01CHUGAI PHARMACEUTICAL : - A STAR Joint Development Project for Anti-Dengue Virus..
AQ
04/01CHUGAI PHARMACEUTICAL : Files an Application for Expanded Use of Genomic Mutatio..
AQ
03/29CHUGAI PHARMACEUTICAL : Position and Policy Regarding Reduction of the Investmen..
AQ
03/29CHUGAI PHARMACEUTICAL : Personnel Changes
AQ
03/29CHUGAI PHARMACEUTICAL : Notice of Disposal of Treasury Shares as Restricted Stoc..
AQ
More news
Financials (JPY)
Sales 2019 614 B
EBIT 2019 -
Net income 2019 111 B
Finance 2019 232 B
Yield 2019 1,41%
P/E ratio 2019 33,42
P/E ratio 2020 28,22
EV / Sales 2019 5,87x
EV / Sales 2020 5,40x
Capitalization 3 834 B
Chart CHUGAI PHARMACEUTICAL CO LTD
Duration : Period :
Chugai Pharmaceutical Co Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO L
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 10
Average target price 6 955  JPY
Spread / Average Target 1,5%
EPS Revisions
Managers
NameTitle
Tatsuro Kosaka President, CEO & Representative Director
Osamu Nagayama Chairman
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Hisanori Takanashi Manager-R&D Portfolio Management Department
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO LTD11.33%34 221
JOHNSON & JOHNSON8.41%372 522
ROCHE HOLDING LTD.9.68%227 039
PFIZER-9.69%218 852
NOVARTIS7.44%195 750
MERCK AND COMPANY-2.20%192 697